Zymeworks Inc.
Index- P/E- EPS (ttm)-4.09 Insider Own6.68% Shs Outstand66.35M Perf Week-10.37%
Market Cap328.80M Forward P/E- EPS next Y-2.83 Insider Trans0.00% Shs Float53.44M Perf Month-25.04%
Income-237.00M PEG- EPS next Q-0.88 Inst Own80.70% Short Float13.14% Perf Quarter-13.89%
Sales31.60M P/S10.40 EPS this Y-14.70% Inst Trans-3.96% Short Ratio9.29 Perf Half Y-24.71%
Book/sh3.35 P/B1.57 EPS next Y27.20% ROA-58.90% Target Price21.61 Perf Year-81.52%
Cash/sh3.88 P/C1.36 EPS next 5Y11.00% ROE-91.80% 52W Range4.11 - 30.18 Perf YTD-67.85%
Dividend- P/FCF- EPS past 5Y-24.10% ROI-86.30% 52W High-81.78% Beta1.14
Dividend %- Quick Ratio3.30 Sales past 5Y19.40% Gross Margin- 52W Low33.82% ATR0.42
Employees284 Current Ratio3.30 Sales Q/Q200.00% Oper. Margin- RSI (14)46.64 Volatility5.99% 8.60%
OptionableYes Debt/Eq0.00 EPS Q/Q25.80% Profit Margin- Rel Volume0.43 Prev Close5.27
ShortableYes LT Debt/Eq0.00 EarningsAug 04 AMC Payout- Avg Volume756.22K Price5.50
Recom1.80 SMA20-1.11% SMA50-9.44% SMA200-28.91% Volume58,698 Change4.36%
May-05-22Upgrade Guggenheim Neutral → Buy $14
Mar-15-22Initiated Evercore ISI Outperform $15
Dec-10-21Upgrade SVB Leerink Mkt Perform → Outperform
Nov-17-21Resumed Guggenheim Neutral
Oct-07-21Initiated Jefferies Hold $32
Mar-31-21Initiated Credit Suisse Outperform $55
Feb-25-21Downgrade SVB Leerink Outperform → Mkt Perform $41
Feb-08-21Resumed H.C. Wainwright Buy $57
Jan-25-21Downgrade Citigroup Buy → Neutral $50 → $53
Sep-29-20Resumed JP Morgan Neutral $48
Aug-06-20Initiated SVB Leerink Outperform $45
Jan-10-20Initiated Wolfe Research Outperform $61
Dec-09-19Initiated JP Morgan Neutral
Nov-25-19Initiated H.C. Wainwright Buy $65
Nov-20-19Initiated Guggenheim Buy
Sep-30-19Upgrade Raymond James Outperform → Strong Buy $36 → $40
Aug-30-19Initiated Stifel Buy $45
Jul-18-19Initiated Deutsche Bank Buy $34
May-11-18Upgrade Barclays Underweight → Equal Weight $8 → $15
Mar-19-18Initiated Raymond James Outperform
Sep-26-22 04:15PM
Sep-16-22 08:30AM
Sep-13-22 09:34AM
Sep-08-22 04:15PM
Sep-04-22 06:05PM
Aug-04-22 08:35PM
Aug-01-22 08:30AM
Jul-27-22 08:45AM
Jul-25-22 08:30AM
Jul-22-22 08:30AM
Jul-21-22 08:30AM
Jul-15-22 08:00AM
Jun-27-22 08:30AM
Jun-10-22 09:57AM
May-27-22 09:57AM
May-26-22 05:00PM
May-20-22 03:13PM
May-19-22 01:00PM
May-04-22 06:25PM
May-03-22 03:27PM
May-02-22 08:30AM
Apr-29-22 10:53AM
Apr-28-22 09:00PM
Apr-27-22 04:15PM
Apr-19-22 04:15PM
Apr-14-22 06:40AM
Apr-06-22 09:26AM
Apr-05-22 04:01PM
Apr-01-22 08:30AM
Mar-03-22 08:30AM
Feb-28-22 06:37AM
Feb-24-22 06:20PM
Feb-17-22 03:02PM
Feb-15-22 05:25PM
Feb-08-22 04:15PM
Feb-03-22 04:15PM
Feb-01-22 04:49AM
Jan-31-22 12:05PM
Jan-27-22 09:16AM
Jan-26-22 09:36PM
Jan-20-22 07:02AM
Jan-19-22 04:15PM
Jan-17-22 07:40AM
Jan-15-22 08:30AM
Jan-14-22 10:10AM
Jan-10-22 06:00AM
Jan-06-22 08:30AM
Jan-05-22 04:30PM
Dec-11-21 01:18PM
Dec-09-21 08:30AM
Dec-08-21 06:00PM
Dec-01-21 08:30AM
Nov-22-21 01:53PM
Nov-19-21 09:21AM
Nov-09-21 04:05PM
Nov-08-21 04:15PM
Nov-03-21 08:05PM
Oct-29-21 11:47AM
Oct-26-21 03:03PM
Oct-25-21 06:06AM
Oct-21-21 11:16AM
Oct-11-21 10:00AM
Sep-17-21 01:52PM
Sep-16-21 11:43AM
Sep-12-21 06:49PM
Sep-03-21 12:23PM
Aug-10-21 09:38AM
Aug-04-21 07:45PM
Aug-03-21 08:30AM
Jul-28-21 03:03PM
Jul-19-21 02:27PM
Jul-13-21 09:22AM
Jul-08-21 08:30AM
May-26-21 08:30AM
May-06-21 08:30AM
May-05-21 08:55PM
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Klompas Neil AChief Operating OfficerMar 10Option Exercise0.005,208016,255Mar 11 09:00 PM
Josephson NeilChief Medical OfficerMar 10Option Exercise0.002,39509,514Mar 11 09:00 PM
Klompas Neil AChief Operating OfficerMar 10Sale6.882,97920,49613,276Mar 11 09:00 PM
Josephson NeilChief Medical OfficerJan 07Buy14.285,00071,3867,119Jan 11 09:47 PM